A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project

Archive ouverte

Molino, Diana | Durier, Christine | Radenne, Anne | Desaint, Corinne | Ropers, Jacques | Courcier, Soizic | Vieillard, Louis Victorien | Rekacewicz, Claire | Parfait, Beatrice | Appay, Victor | Batteux, Frédéric | Barillot, Emmanuel | Cogné, Michel | Combadière, Béhazine | Eberhardt, Christiane | Gorochov, Guy | Hupé, Philippe | Ninove, Laetitia | Paul, Stéphane | Pellegrin, Isabelle | van der Werf, Sylvie | Lefebvre, Maeva | Botelho-Nevers, Elisabeth | Ortega-Perez, Inmaculada | Jaspard, Marie | Sow, Samba | Lelièvre, Jean Daniel | de Lamballerie, Xavier | Kieny, Marie Paule | Tartour, Eric | Launay, Odile

Edité par CCSD ; Nature Publishing Group -

International audience. Significance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion